je.st
news
Tag: therapeutics
NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics
2015-02-23 13:00:00| Merck.com - Corporate News
Dateline City: SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J. Partnership Combines NGMs Unique Biology-focused Research Platform with Mercks Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)-- NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Language: English Contact: MerckMedia Relations:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestor Relations:Justin Holko, 908-740-1879orNGM BiopharmaceuticalsMedia Relations:Tony Plohoros, 908-940-01356 Degreestplohoros@6degreespr.comorInvestor Relations:Beth DelGiacco, 212-362-1200Stern Investor Relationsbeth@sternir.com Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: develop
broad
discover
collaboration
Weekly CEO Sells Highlight: Kimberly-Clark Corp, Regulus Therapeutics Inc, Prologis Inc, and ...
2015-02-02 05:25:11| Paper - Topix.net
According to GuruFocus Insider Data , these are the largest CEO sales during the past week: Kimberly-Clark Corp, Regulus Therapeutics Inc, Prologis Inc, and Adobe Systems Inc. Kimberly-Clark Corp : Chairman of the Board and CEO Thomas J Falk sold 156,488 Shares Chairman of the Board and CEO of Kimberly-Clark Corp Thomas J Falk sold 156,488 shares on 01/27/2015 at an average price of $110.2. Kimberly-Clark Corp was incorporated in Delaware in 1928. Kimberly-clark Corp has a market cap of $43.03 billion; its shares were traded at around $107.96 with a P/E ratio of 26.70 and P/S ratio of 2.32.
Dolomite's Microfluidics Technology Helping to Advance Antibody Therapeutics
2015-01-16 11:30:53| Industrial Newsroom - All News for Today
Dolomite's droplet generation system is helping AbVitro to identify potential therapeutic targets using its AbPair technology. Dr Adrian Briggs, Director of Molecular Biology RD at AbVitro, commented: "Our aim is to develop new potential targets and therapies for a wide range of diseases, taking advantage of the...
Tags: technology
advance
helping
antibody
Aldeyra Therapeutics Announces $7.79 Million Private Placement
2015-01-13 22:38:51| Industrial Machines - Topix.net
Aldeyra Therapeutics, Inc. , a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement to raise approximately $7.79 million in a private placement of common stock and warrants . Aldeyra plans to use the proceeds for its upcoming Phase 2 clinical trials in Sjogren-Larsson Syndrome and noninfectious anterior uveitis, working capital, and general corporate purposes.
Tags: private
million
placement
announces
Buzz Stocks: Infosys Limited, Revance Therapeutics, Inc., and Steven Madden, Ltd.
2015-01-10 09:47:40| Footwear - Topix.net
In company news, today's stocks to watch include IT services firm Infosys Ltd ADR , drugmaker Revance Therapeutics Inc , and shoe designer Steven Madden, Ltd. . INFY reported a fiscal third-quarter earnings beat , thanks to strong demand from U.S.-based clients.
Tags: ltd
limited
steven
stocks
Sites : [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] next »